Tyramine: A Comprehensive Reference
1. Identity and Chemical Characterization
Names and Classification
Tyramine (pronounced TY-rə-meen; also spelled tyramin) is a naturally occurring trace amine derived from the amino acid tyrosine. It is also known as 4-hydroxyphenethylamine and para-tyramine, and can be formed from tyrosine by the action of the ubiquitous enzyme aromatic amino acid decarboxylase (AAADC). Its molecular formula is C₈H₁₁NO, and it has a sympathomimetic action.
Tyramine is a trace monoamine with sympathomimetic properties, naturally found in foods, plants, and animals. By definition, all monoamines have an amine group separated from an aromatic ring by a 2-carbon chain — as do dopamine, norepinephrine, and serotonin. Trace monoamines were named for their relatively low frequency in mammalian tissues compared to their more abundant monoamine neurotransmitter counterparts: epinephrine, norepinephrine, dopamine, and serotonin. Other trace amines include octopamine, phenethylamine, N-methylphenethylamine, and N-methyltyramine.
According to chemical structure, biogenic amines can be classified as aromatic (tyramine and 2-phenylethylamine), aliphatic (putrescine, cadaverine, spermine, and spermidine), or heterocyclic (histamine and tryptamine). Tyramine is a colorless crystalline amine derived from phenol, found in ripe cheese, ergot, decayed animal tissue, and mistletoe.
Etymology and Early Isolation
Tyramine was first isolated from cheese and later named after the Greek word tyros, meaning "cheese." The name reflects the same etymological root as its precursor amino acid: the word "tyrosine" is from the Greek tyrós, meaning "cheese," as it was first discovered in 1846 by German chemist Justus von Liebig in the protein casein from cheese. Tyramine was the first known substrate of monoamine oxidase (MAO).
Natural Occurrence and Sources
Tyramine is formed through decarboxylation of tyrosine by microbes, and is thus found in numerous fermented, aged, or ripened protein-rich food products. Tyramine levels increase in foods when they are aged, fermented, stored for long periods of time, or are not fresh.
Specific foods containing considerable amounts of tyramine include: strong or aged cheeses (cheddar, Swiss, Parmesan, Stilton, Gorgonzola, blue cheeses, Camembert, feta, Muenster); meats that are cured, smoked, or processed (salami, pepperoni, dry sausages, hot dogs, bologna, bacon, corned beef, pickled or smoked fish, caviar, aged chicken livers, soups or gravies made from meat extract); pickled or fermented foods (sauerkraut, kimchi, tofu, pickles, miso soup, bean curd, tempeh, sourdough breads); condiments (soy, shrimp, fish, miso, teriyaki, and bouillon-based sauces); and drinks (beer, especially tap or home-brewed, vermouth, red wine, sherry, liqueurs).
Among fermented foods, cheese and dry-fermented sausages are generally associated with the presence of large amounts of biogenic amines, especially tyramine, ranging from not detected to values higher than 600 mg kg⁻¹. In fermented beverages such as wine and beer, tyramine and histamine contents are much lower, usually not exceeding 5 mg l⁻¹, although in some cases histamine levels have reached approximately 50 mg l⁻¹.
Biogenic amines such as tyramine are not normally present in measurable amounts in fresh, wholesome foods but result from the degradation of amino acids present in aging or deteriorating foods; their measurement in foods increases in the presence of poor hygiene, temperature abuse, or storage time abuse.
Endogenous Production
Many biogenic amines, such as tyramine, are present in nanomolar concentrations in blood plasma and in the central nervous systems — mainly in neurons — of healthy people. Because of its high sensitivity to oxidation by MAO, tyramine's endogenous levels are very low, and it is one of a group of biogenic amines referred to as "trace amines."
2. Biosynthesis and Biochemistry
Enzymatic Formation
Tyrosine decarboxylase (TDC) is a pyridoxal 5-phosphate (PLP)-dependent enzyme and is mainly responsible for the synthesis of tyramine. Tyramine is derived from the amino acid tyrosine through the action of the enzyme tyrosine decarboxylase, which catalyzes the decarboxylation of tyrosine, resulting in the formation of tyramine. In foods, biogenic amines are mainly produced through the decarboxylation of amino acids by lactic acid bacteria (LAB).
Lactic acid bacteria (LAB) are considered the main biogenic amine producers in fermented foods. Most tyramine-producing strains found in fermented soybean foods were found to belong to Bacillus; specifically, Bacillus cereus and Millerozyma farinosa were identified as crucial producers in soy sauce.
Metabolism and Elimination
Tyramine is mainly metabolized by the enzyme monoamine oxidase (MAO) in the liver and other tissues, leading to the production of metabolites such as 4-hydroxyphenylacetaldehyde. Normally, tyramine ingested in the diet is metabolized by monoamine oxidase in the gut and liver and conjugated by enzymes, so that it fails to enter the systemic circulation.
On average, as much as 76.8% of a dose of tyramine is recovered in urine in the form of the MAO-catalyzed metabolite 4-hydroxyphenylacetic acid (4-HPAA), confirming that oxidative deamination by MAO-A is the quantitatively most relevant metabolic pathway. Tyramine oxidase occurs in high concentrations in intestinal mucosa.
3. Traditional and Historical Use
Pre-Scientific Context
Tyramine itself has no documented tradition of deliberate, isolated therapeutic use. It occurs as an unavoidable constituent of fermented and aged foods that have been central to human diets for millennia. Microbial fermentation is one of the oldest and most practical technologies used in food processing and preservation. Cheese, wine, fermented meats, miso, soy sauce, kimchi, and sauerkraut — all traditional foods of multiple civilizations — produce tyramine as a natural byproduct of their preparation.
The adverse effects resulting from the absorption of some of these pressor amines was described by Metchinkoff as early as in 1905. However, the specific identification of tyramine as a pharmacologically active constituent within these foods came much later, tied to 20th-century pharmacology. Traditionally, biogenic amine formation in food has been prevented primarily by limiting microbial growth through chilling and freezing.
Discovery of Clinical Significance: The "Cheese Reaction"
Blackwell first described the interaction between MAOI drugs and tyramine in 1963 and named it the "cheese reaction." The tyramine connection was discovered by a British pharmacist whose wife was taking a monoamine oxidase inhibitor; he noticed that every time they had a meal with cheese, she would get a severe headache — and cheese, especially aged cheese, contains a substantial amount of tyramine.
A psychiatric resident, Barry Blackwell, at Maudsley Hospital in London formally reported 12 patients who had hypertensive crises apparently related to the use of Parnate (11 patients) or Nardil (one patient). In 1965, in their seminal article, Blackwell and co-workers showed that tyramine in cheese is related to hypertensive crises after MAO inhibition. Since that identification, several hundred articles have addressed the biogenic amine content of foods.
The historical context of the discovery includes the serendipitous identification of the antidepressant action of iproniazid, an antitubercular drug that was also found to inhibit MAO. This brings the history back to the 1950s and the "psychic energizing" action of iproniazid, which also inhibited MAO, leading eventually to Blackwell's seminal research.
4. Key Constituents, Active Compounds, and Mechanisms of Action
Structure and Receptor Interactions
Tyramine is a norepinephrine and dopamine releasing agent (NDRA) and indirectly acting sympathomimetic. Notably, it is unable to cross the blood-brain barrier, resulting in only non-psychoactive peripheral sympathomimetic effects following ingestion.
Tyramine functions as an indirect sympathomimetic by promoting the release of noradrenaline from synaptic vesicles, thereby having hypertensive effects — a phenomenon referred to as the tyramine pressor response. Tyramine exerts its vasopressor response as an indirectly acting sympathomimetic agent, taken up by the NET (norepinephrine reuptake transporter), which precipitates the release of large quantities of norepinephrine into circulation.
Trace Amine-Associated Receptor 1 (TAAR1)
The Gs-linked G-protein coupled receptor Trace Amine-Associated Receptor 1 (TAAR1) is a target for a wide variety of agonists including endogenous amines and amphetamine-like drugs of abuse; endogenous agonists include common biogenic amines as well as trace amines. The TAAR1 protein responds well to beta-phenylethylamine, p-tyramine, octopamine, and tryptamine, but responds little or not at all to dopamine, serotonin, epinephrine, or histamine.
TAAR1 is a G protein-coupled receptor which signals through elevating intracellular cAMP levels, and is expressed in most vertebrates, including rodents and humans. Multiple lines of evidence suggest that TAAR1 plays a significant role in modulation of central dopaminergic neurotransmission and function, by influencing processes at the levels of dopaminergic cell bodies and terminals in the dorsal and ventral striatum; the overall effect of TAAR1 activation is inhibitory with respect to the dopamine system.
Tyramine could act as an endogenous ligand for mammalian trace amine-associated receptors and as a biochemical precursor for dopamine and octopamine, which are neurotransmitters and neuromodulators in invertebrate nervous systems.
Adrenergic Mechanism
When an MAOI irreversibly binds to MAO-A, the degradation of tyramine in the digestive system is prevented, allowing an excess of tyramine to enter the bloodstream and be metabolized into norepinephrine. Norepinephrine then stimulates postsynaptic α₁ and other adrenergic receptors and the cardiovascular sympathetic nervous system, constricting blood vessels. When the blood pressure increase is large and sudden, a hypertensive crisis can occur; hypertensive crisis is defined as having a systolic blood pressure greater than 180 mm Hg or a diastolic blood pressure greater than 120 mm Hg, which can cause permanent damage to organs, stroke, aneurysm, and rarely death.
Effects in Adipose Tissue
Tyramine acts on adipose tissues and has a dose-dependent antilipolytic effect. This observation, from peer-reviewed biochemistry literature, suggests a peripheral metabolic role beyond the cardiovascular system, though human clinical implications remain under investigation.
5. Scientific Evidence by Area of Use
5.1 Cardiovascular Effects: The Tyramine Pressor Response
Evidence level: Well-established, direct human clinical data.
The pharmacokinetics, pharmacodynamics, and pharmacogenetics of tyramine were studied in 88 healthy volunteers after oral administration of a 400 mg dose. The study observed a strong interindividual variation in systemic tyramine exposure, with a mean AUC of 3.74 min*µg/ml and a high mean CL/F ratio of 107 l/min. Systolic blood pressure increased by more than 10 mmHg in 71% of the volunteers and correlated strongly with systemic tyramine concentration; in less than 10% of participants, blood pressure peaks greater than 40 mmHg above baseline were observed at tyramine concentrations greater than 60 µg/l.
The average person can tolerate roughly 400 mg of ingested tyramine before postsynaptic adrenergic receptors undergo excessive stimulation resulting in elevated blood pressure. Those on an MAOI have a heightened sensitivity to tyramine because MAOIs inhibit MAO-A, and when MAO-A is inhibited, the capacity to handle tyramine intake from the diet is significantly reduced, causing the brain to be vulnerable to overstimulation of postsynaptic adrenergic receptors with as little as 8–10 mg of tyramine ingested.
Tyramine-MAOI reactions are usually rapid in onset, occurring within 15–90 minutes after ingestion; most symptoms resolve in 6 hours, although fatalities are rare but have been reported due to complications from hypertensive emergencies.
5.2 Tyramine Challenge Studies: MAO-B Inhibitors and Transdermal Selegiline
Evidence level: Direct human Phase I clinical trial data.
A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain while preserving the gastrointestinal MAO-A barrier; a study was conducted to determine the effect of the STS 6 mg/24 hour on cardiovascular safety following the ingestion of approximately 400 mg of tyramine consumed as a component of aged cheeses. Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects; no evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred, suggesting the STS may be administered without concern for dietary tyramine consumption.
Nonselective, irreversible MAOIs such as phenelzine and tranylcypromine are associated with an increased risk of hypertensive crisis when ingested with tyramine-rich foods; in contrast, selective monoamine oxidase B inhibitors, such as selegiline, have a lower risk of hypertension. Deprenyl (selegiline), a specific MAO-B inhibitor at low doses of 10 mg/day, can be administered safely with dietary tyramine.
5.3 Tyramine and Migraine
Evidence level: Weak; controlled studies show largely negative results; systematic review evidence inconclusive.
Although not completely understood, tyramine-containing foods are known triggers for patients with migraines; the adrenergic effects of tyramine may be responsible for the migraine phenomena, and diets low in tyramine can be recommended when aiming to identify migraine triggers.
However, direct interventional evidence is weak. In a double-blind study of 80 migraine patients, headache was precipitated by ingestion of 200 mg tyramine and not by placebo in eight individuals, but retesting of seven of these patients did not produce the same results. Placebo produced as severe headache as tyramine and in an even larger number of patients. The conclusion was that dietary tyramine alone is rarely, if ever, the major precipitant of a migraine attack, although the possibility remains that it has such a role in the presence of particular physiologic states.
A systematic review that included seven non-randomized studies with 322 eligible subjects aged 4 to 62 years found a high to moderate (17.2–50%) occurrence of headache after tyramine ingestion; however, six studies had a moderate risk of bias and one a serious risk of bias, leading to the conclusion that the relationship between tyramine-containing food and migraine remains unclear.
A dose of 10 mg tyramine has been associated with migraine onset; however, levels of 6 mg can cause migraine in patients under treatment with MAO inhibitors. The precise mechanism behind how tyramine can trigger migraines is not clear.
5.4 TAAR1-Mediated Neuropsychiatric Implications
Evidence level: Predominantly preclinical (animal and in vitro); human relevance under investigation.
TAAR1 has been implicated in human conditions including obesity, schizophrenia, depression, fibromyalgia, migraine, and addiction. In brain, TAAR1 stimulation reduces synaptic dopamine availability and alters glutamatergic function. With regards to dopaminergic system-related potential therapeutic utility, TAAR1 agonists have demonstrated activity in animal models pertinent to schizophrenia and addiction. These findings, however, relate primarily to synthetic TAAR1 agonists, not to tyramine itself as a therapeutic agent. The role of trace amine-associated receptors and their biogenic amine ligands in physiologic concentrations, such as tyramine, requires additional study.
5.5 Immune System Interactions
Evidence level: Preliminary; in vitro and animal data only.
TAAR1 and TAAR2 are expressed in human polymorphonuclear leukocytes; a chemosensory migration by these leukocytes according to the trace amine concentration gradient (including tyramine) was demonstrated. Studies in mouse bone marrow-derived macrophages showed increased expression of TAAR1 after exposure to tyramine; increased transcription of genes for pro-inflammatory cytokines including IL-6, TNFα, and IL-1β was also detected. New evidence suggests endogenous tyramine and other trace amines in lower physiologic levels may have additional roles, including modulating the immune system. These findings are preliminary and have not yet been translated into clinical human studies.
5.6 Glucose Homeostasis: Animal Data
Evidence level: Preclinical only; no human data available.
In mice, researchers investigated whether prolonged tyramine ingestion could alter glucose homeostasis, insulin sensitivity, adipose tissue physiology, or cardiovascular functions; tyramine was added at 0.04% or 0.14% in drinking water, estimated to increase spontaneous tyramine intake 10- to 40-fold. Ten to 12 weeks of tyramine supplementation did not influence body weight gain, adiposity, or food consumption; both doses decreased nonfasting blood glucose but did not modify glucose tolerance or fasting levels of glucose, insulin, or circulating lipids. These are mouse data and cannot be directly extrapolated to humans.
6. Pharmacokinetics and Interindividual Variability
In a pharmacogenetic study, the pharmacokinetics, pharmacodynamics, and pharmacogenetics of tyramine were studied in 88 healthy volunteers after oral administration of a 400 mg dose; a strong interindividual variation in systemic tyramine exposure was observed, with a mean AUC of 3.74 min*µg/ml and a high mean CL/F ratio of 107 l/min.
Unexpectedly, the functionally relevant polymorphisms in OCT1 and CYP2D6, including the CYP2D6 poor and ultra-rapid metabolizer genotypes, did not significantly affect tyramine pharmacokinetics or pharmacodynamics; the MAO-A genotypes, which had been associated in several earlier studies with neuropsychiatric phenotypes, also had no significant effects on tyramine pharmacokinetics or its metabolism to 4-HPAA. This finding indicates that the high interindividual variability in tyramine response is not simply explained by common genetic polymorphisms in these enzymes.
7. Body Systems and Health Areas
Cardiovascular System
Tyramine is known for its physiological effects on the body, particularly its impact on the cardiovascular and nervous systems. Trace levels of TAAR1 were detected in the cardiovascular system, both in the rat heart and aorta, where it could mediate trace amine-induced vasoconstriction and elevation of blood pressure. TAAR1 is also expressed at low levels in heart, and may regulate cardiovascular tone.
Central Nervous System
TAAR1 is expressed in the central nervous system in the ventral tegmental area (VTA), substantia nigra, dorsal raphe nucleus, amygdaloid body, renal cortex of the medial temporal lobe, base of the hippocampus, prefrontal cortex, nucleus accumbens, and hypothalamus. TAAR1 plays a significant role in regulating neurotransmission in dopamine, norepinephrine, and serotonin neurons in the CNS; it also affects immune system and neuroimmune system function through different mechanisms.
Gastrointestinal System
Under normal conditions, exogenous biogenic amines ingested with food are rapidly detoxified by the action of amine oxidases; but whenever the detoxification process is disturbed, or the biogenic amine concentration in food is very high, they become toxic metabolites responsible for serious human health problems. When patients take MAOIs, MAO-A activity in the gut and liver is significantly and persistently inhibited; large amounts of unmetabolized tyramine are then able to escape first-pass elimination and enter the systemic circulation directly, reaching peripheral sympathetic nerve endings and triggering the bursting release of large amounts of norepinephrine into the synaptic gap.
Immune System
TAAR1 gene transcripts were, jointly with TAAR2, the most abundant in human polymorphonucleates and lymphocytes, suggesting a potential role in immune functions. The ability of TAAR1 to signal in response to endogenous common biogenic amines and trace amines implicates the receptor as a mediator of aminergic regulation of immune function.
8. Dosage Forms and Doses Reported in Studies
Tyramine is not typically used as a stand-alone dietary supplement with standardized dosing. Its relevance in clinical research relates primarily to pharmacological challenge studies and food safety. The following doses appear in the peer-reviewed literature:
- Pharmacokinetics and pharmacodynamics were studied in 88 healthy volunteers after oral administration of a 400 mg dose of tyramine.
- Ingestion of 10 to 25 mg of tyramine in patients taking MAOIs produces a severe adrenergic response, including hypertension, headaches, and possible intracranial hemorrhage.
- A dose of 10 mg tyramine has been associated with migraine onset; however, levels of 6 mg can cause migraine in patients under treatment with MAO inhibitors.
- The average person without MAOI treatment can tolerate roughly 400 mg of ingested tyramine before postsynaptic adrenergic receptors undergo excessive stimulation resulting in elevated blood pressure.
- Even the administration of very low doses of tyramine — e.g., 5 mg — may rapidly induce severe or even fatal hypertensive crises in the presence of MAOIs, especially irreversible nonselective MAOIs.
- In a double-blind study of 80 migraine patients, 200 mg of tyramine was administered orally; headache was precipitated in eight individuals, but retesting of seven of these patients did not reproduce the same results.
- The effect of selegiline transdermal system 6 mg/24 hr on cardiovascular safety was assessed following the ingestion of approximately 400 mg of tyramine consumed as a component of aged cheeses.
- In a mouse study, tyramine supplementation at doses reaching approximately 300 and 1,100 µmol/kg body weight/day decreased nonfasting blood glucose but did not modify glucose tolerance or fasting levels of glucose, insulin, or circulating lipids.
9. Safety Considerations and Drug Interactions
The Cheese Effect / Tyramine-MAOI Hypertensive Crisis
In combination with monoamine oxidase (MAO) inhibitors, tyramine can cause a so-called hypertensive crisis that, besides symptoms like headache, migraine, nausea, or vomiting, may even cause end-organ damage, intracerebral haemorrhage, and death.
Despite the varied and diverse uses of MAOIs, there remains a discrepancy between the benefits offered by MAOI treatment and the actual clinical utilization of these drugs, partly because of the "cheese effect" or hypertensive crisis. Nonselective, irreversible MAOIs such as phenelzine and tranylcypromine are associated with an increased risk of hypertensive crisis when ingested with tyramine-rich foods.
MAOIs are known to cause hypertensive crisis when combined with soft cheese due to unopposed release of catecholamines from reduced tyramine metabolism, leading to injury and possible myonecrosis; three previous case reports have demonstrated either creatinine kinase or troponin rise with myocardial infarction due to this hypertensive crisis.
MAO-B Inhibitors and Reduced Risk
Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine. Specific MAO-B inhibitors are thought to have a better safety profile, as MAO-A activity in the gut is not inhibited.
Synergistic Toxicity with Histamine
The dietary biogenic amines tyramine and histamine show synergistic toxicity towards intestinal cells in culture. Co-ingestion of multiple biogenic amines in fermented foods may therefore pose a greater risk than either amine in isolation.
Symptom Onset and Resolution
Symptoms of tyramine excess are evident 1–12 hours after ingestion of food containing tyramine. The MAOI-tyramine reaction is usually rapid in onset, occurring within 15–90 minutes after ingestion, and most symptoms resolve in 6 hours.
Cardiovascular Risk Factors
MAOIs can trigger a hypertensive crisis if patients consume foods or beverages high in tyramine, and the risk is increased in individuals with hyperthyroidism or preexisting cardiovascular or cerebrovascular disease.
Interindividual Variability
A strong interindividual variation in systemic tyramine exposure exists. Despite initial hypotheses, the functionally relevant polymorphisms in OCT1 and CYP2D6, including the CYP2D6 poor and ultra-rapid metabolizer genotypes, did not significantly affect tyramine pharmacokinetics or pharmacodynamics; the MAO-A genotypes had no significant effects on tyramine pharmacokinetics. The biological basis of this variability therefore remains incompletely understood.
Dietary Management During MAOI Therapy
Tyramine is often found in fermented, aged, cured, and spoiled foods; ingestion of high tyramine-containing foods in patients taking MAOIs produces headaches, blurry vision, chest pain, and palpitations associated with hypertension and intracranial hemorrhages. Modern improvements in food storage decrease tyrosine decarboxylase activity, further reducing tyramine levels in modern foods. Potential new drugs known or suspected to inhibit MAO are usually assessed for potential interactions with oral tyramine in clinical studies.
Food Safety Context
Tyramine and other biogenic amines derived from amino acid decarboxylation through microbial activities can cause toxic effects on humans, with symptoms (headache, heart palpitations, vomiting, diarrhea) depending also on individual sensitivity. Despite the toxicity of biogenic amines, their limit concentrations in fermented foodstuffs have not yet been adequately standardized by regulatory agencies. Scientists increasingly consider tyramine in food as an aspect of safety; they propose projects of regulation aimed to enact control of biogenic amines in food by various strategies, including usage of proper fermentation starters or preventing their decarboxylase activity, and some authors indicate tyramine content in food is now lower than it has been in the past.
References
Go back